Ubiquigent

We are in the process of transferring the Ubiquigent brand to a new owner, who may, in due course, provide future support to UPS research worldwide. We wish you all well with your future research and scientific endeavours.

To all our valued customers, collaborators, partners and suppliers, we regret to inform you that Ubiquigent Limited is no longer providing access to high-quality, validated reagents or services to support your Ubiquitin Proteasome System (UPS) related research.

@o2h_discovery will provide Ubiquigent with access to chemists and associated expertise to support its development of a novel portfolio of DUB-targeting compounds to enable the development of DUB-based therapeutics in partnership with its pharma and biotech partners.

We’re excited to announce that we have won an o2h Kickstarter Award ubiquigent.com/posts/ubiquige… #enabling #partnerships #DUB #deubiquitinase @o2h_discovery

Last call to submit to our DUBprofiler Open Access Initiative! Submit your DUB inhibitors for screening - gain insights into your non-proprietary compounds’ potency & selectivity to ensure your research & #drugdiscovery programmes have a strong foundation: services@ubiquigent.com

Interested in learning more about the potency & selectivity of your compounds? Join our DUBprofiler Open Access Initiative & submit non-proprietary DUB modulators for screening against our gold standard #assay before 31 Jan. 💻 bit.ly/4f8GDOP 📩 services@ubiquigent.com

📢Ubiquigent launches DUBprofiler Open Access Initiative Many #DUB inhibitors in the public domain have inadequately characterised selectivity. To counter this, we're inviting scientists to submit non-proprietary compounds for characterisation at no cost: bit.ly/4f8GDOP

@AcceleroB Using DUBprofiler-Cell and DUBprofiler-Tissue, we supported a partner to determine target engagement & selectivity of their compound in biochemical, cell-based and preclinical animal studies. 📄Read more: rb.gy/3oo82

It’s great to see more and more exciting companies working in the DUB space! 🤝 Mid-Atlantic BioTherapeutics and @AcceleroB combine neurological #drugdiscovery and high-throughput protein X-ray crystallography based fragment screening to develop USP30 inhibitors for Parkinson’s.

@AcceleroB 🏆@VincereBio was awarded a $500k grant from @MichaelJFoxOrg and received the NINDS SBIR Phase I award for its project ‘In vivo evaluation of USP30 inhibitors in models relevant to Parkinson’s disease’

@AcceleroB 💰 Earlier in the year, @MISSIONTherapeu received funding from @MichaelJFoxOrg and @ParkinsonsUK to advance MTX325 through clinical trials. The USP30 inhibitor offers a potential treatment for early-stage Parkinson’s disease.

We had a great time at #BIOEurope Autumn! 🍂 In case you missed us, there’s still time to schedule a meeting during the virtual partnering event on 12-13 November – contact us at info@ubiquigent.com to find out more. #DrugDiscovery #DrugDevelopment #Pharma #Biotech #DUB

At Ubiquigent, we are accelerating our partners’ DUB-focused drug discovery programmes across core therapeutic areas, using our comprehensive suite of assays to identify and characterise novel DUB-modulating compounds: ubiquigent.com/platform #USP30 #DUBs #DrugDiscovery

USP30 is a DUB enzyme which is an actionable drug target for diseases associated with mitochondrial dysfunction, including Parkinson’s disease, with many companies exploring opportunities for USP30 inhibition.

#BIOEurope has kicked off, bringing together industry leaders to discuss the future of biotech. Our team have a busy week ahead, meeting with partners, customers, and potential investors to share insights into our novel approach to DUB-focused #drugdiscovery.📩info@ubiquigent.com

Next week, Hozefa Amijee and Rishi Shah will be at #BIOEurope,discussing how we are using our industry-leading platform to build a portfolio of novel DUB-targeting compounds to accelerate our partners’ programmes. Learn more: 💻ubiquigent.com 📩 Info@ubiquigent.com

We’re delighted to be partnering with @AlleoLabs to accelerate DUB-focused drug discovery! This collaboration will combine Alleo’s AI-based platform with our expertise in the DUB space to advance DUB-focused preclinical programmes. ➡ tinyurl.com/283d7o5o

@IcahnMountSinai To find out more about how we are using our DUB-focused drug discovery platform to develop novel DUBTACs, get in touch: info@ubiquigent.com #DUBTACs #ubiquitin #oncology

🧾Novel DUBTACs to stabilise cGAS! Researchers at @IcahnMountSinai have generated a novel #DUBTAC to stabilise cGAS, causing activation of downstream signalling and suppression of #cancer cell growth and colony formation. Read more: rb.gy/ehx5gu

🔔 Last chance to take advantage of our anniversary sale! Join us in celebrating 15 years of supporting researchers with a minimum 15% discount on all orders of our custom ubiquitin proteasome reagents until 31 Aug. 💻 rb.gy/35clhh 📩 sales.support@ubiquigent.com